Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apraglutide in steroid-refractory gastrointestinal acute graft-versus-host disease
2021-004588-29Phase 2Active
- Sponsor
- VectivBio
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of apraglutide in Acute Graft-Versus-Host Disease (aGvHD) and graft-versus-host disease (GVHD) (2 arms), sponsored by VectivBio. Primary endpoint: Adverse events. Started Oct 2021; status: active.
02
Drugs
apraglutide
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2021-004588-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004588-29.